Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial
Diabetes, Obesity and Metabolism · 2023-07 · 25 (7) · 1865-1873
DOI: 10.1111/dom.15046 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.03.2023. Verfasst von Soo Heon Kwak und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daewoong Pharmaceutical Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims To evaluate the efficacy and safety of a novel sodium‐glucose cotransporter 2 inhibitor, enavogliflozin 0.3 mg monotherapy, in Korean people with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise. Materials and Methods This study was a randomized, double‐blind, placebo‐controlled trial conducted in 23 hospitals. Individuals with haemoglobin A1c (HbA1c) of 7.0%‐10.0% after at least 8 weeks of diet and exercise modification were randomized to receive enavogliflozin 0.3 mg (n = 83) or placebo (n = 84) for 24 weeks. The primary outcome was a change in HbA1c at week 24 from baseline. Secondary outcomes included the proportion of participants achieving HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
- Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea.
- Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
- Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea.
- Department of Internal Medicine, Ulsan University Hospital, College of Medicine University of Ulsan, Ulsan, South Korea.
- Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, South Korea.
ORCID-Profile: Kyung-Soo Kim, Choon Hee Chung, Sin Gon Kim, Seung Ah Cho, Bo Young Cho
Förderung
- Daewoong Pharmaceutical Company
Zitieren
APA
Kwak, S. H., Han, K. A., Kim, K. S., Yu, J. M., Kim, E., Won, J. C., Kang, J. G., Chung, C. H., Oh, S., Choi, S. H., Won, K. C., Kim, S. G., Cho, S. A., Cho, B. Y., & Park, K. S. (2023). Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial. Diabetes, Obesity and Metabolism, 25(7), 1865-1873. https://doi.org/10.1111/dom.15046
Vancouver
Kwak SH, Han KA, Kim KS, Yu JM, Kim E, Won JC, et al. Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial. Diabetes, Obesity and Metabolism. 2023;25(7):1865-1873. doi:10.1111/dom.15046
BibTeX
@article{Kwak2023,
author = {Kwak, Soo Heon and Han, Kyung Ah and Kim, Kyung-Soo and Yu, Jae Myung and Kim, EunSook and Won, Jong Chul and Kang, Jun Goo and Chung, Choon Hee and Oh, Seungjoon and Choi, Sung Hee and Won, Kyu Chang and Kim, Sin Gon and Cho, Seung Ah and Cho, Bo Young and Park, Kyong Soo},
title = {Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {7},
pages = {1865--1873},
doi = {10.1111/dom.15046}
}
EUVIMED